CRISPR Therapeutics (NASDAQ:CRSP) Stock: Insider James Kasinger Sells 1,990 Shares

CRISPR Therapeutics AG (NASDAQ:CRSP) General Counsel James Kasinger sold 1,990 shares of the stock in a transaction dated Tuesday, October 6th. The stock was sold at an average price of $60.04, for a total transaction of $119,479.60. Following the completion of the sale, the general counsel directly owned 94,784 shares in the company, valued at approximately $5,690,831.36. The trade was a 2.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

CRISPR Therapeutics Price Performance

Shares of NASDAQ:CRSP opened at $53.39 on Friday. The company has a 50 day moving average of $55.14 and a 200 day moving average of $53.08. The stock has a market cap of $5.16 billion, a P/E ratio of -11.22 and a beta of 1.76. CRISPR Therapeutics AG has a 12 month low of $44.12 and a 12 month high of $78.00. The company has a current ratio of 17.85, a quick ratio of 17.85 and a debt-to-equity ratio of 0.34.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Tuesday, June 30th. The company reported ($0.94) earnings per share (EPS) for the quarter. CRISPR Therapeutics had a negative return on equity of 24.39% and a negative net margin of 3,368.72%. The firm had revenue of $10.18 million during the quarter. As a group, sell-side analysts forecast that CRISPR Therapeutics AG will post -4.47 EPS for the current fiscal year.

Key Stories Impacting CRISPR Therapeutics

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: Analyst price targets remain well above the current trading level. BofA trimmed its target modestly to $81 from $82 while maintaining a Buy rating. Separately, Citi sees approximately 60% upside, although that potential depends on three key developments going as planned. BofA Adjusts Price Target on CRISPR Therapeutics to $81 From $82, Keeps Buy Rating Citi Sees 60% Upside in CRISPR Therapeutics. Here’s What Has to Go Right.
• Positive Sentiment: CRISPR Therapeutics will present late-breaking Phase 1b data for CTX310 at the American Heart Association Scientific Sessions on November 9. The in vivo CRISPR/Cas9 therapy targets ANGPTL3 for severe hypertriglyceridemia, making the presentation a potentially important clinical catalyst. CRISPR Therapeutics to Present Late-Breaking Data at the AHA Scientific Sessions 2026
• Neutral Sentiment: Wall Street’s overall view is Moderate Buy. The consensus target price is $67.94, supported by two Strong Buy, nine Buy, six Hold, and one Sell rating. This indicates generally favorable sentiment, but also meaningful disagreement about the company’s valuation and clinical risk. CRISPR Therapeutics Stock Now Rated Moderate Buy by Wall Street Analysts
• Negative Sentiment: General Counsel James Kasinger sold 1,990 shares for approximately $119,480. The transaction reduced his holdings by 2.06%, which could weigh modestly on sentiment, though he retained 94,784 shares and the sale does not by itself indicate a change in company fundamentals. CRISPR Therapeutics General Counsel Sells Stock

Hedge Funds Weigh In On CRISPR Therapeutics

A number of large investors have recently modified their holdings of the company. GAMMA Investing LLC raised its stake in shares of CRISPR Therapeutics by 92.0% during the third quarter. GAMMA Investing LLC now owns 1,246 shares of the company’s stock worth $69,000 after acquiring an additional 597 shares in the last quarter. Green Alpha Advisors LLC boosted its stake in shares of CRISPR Therapeutics by 1.8% in the 3rd quarter. Green Alpha Advisors LLC now owns 56,786 shares of the company’s stock valued at $3,141,000 after purchasing an additional 982 shares in the last quarter. Farther Finance Advisors LLC boosted its stake in shares of CRISPR Therapeutics by 43.6% in the 3rd quarter. Farther Finance Advisors LLC now owns 11,426 shares of the company’s stock valued at $632,000 after purchasing an additional 3,470 shares in the last quarter. Congress Asset Management Co. grew its holdings in shares of CRISPR Therapeutics by 1.6% during the 3rd quarter. Congress Asset Management Co. now owns 111,230 shares of the company’s stock valued at $6,153,000 after purchasing an additional 1,777 shares during the last quarter. Finally, Versant Capital Management Inc lifted its stake in CRISPR Therapeutics by 131.8% in the third quarter. Versant Capital Management Inc now owns 1,078 shares of the company’s stock worth $60,000 after purchasing an additional 613 shares during the last quarter. 69.20% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Needham & Company LLC reissued a “buy” rating and set a $82.00 price objective on shares of CRISPR Therapeutics in a research note on Monday, August 31st. Wall Street Zen upgraded shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. UBS Group reiterated a “buy” rating on shares of CRISPR Therapeutics in a research report on Friday. HC Wainwright reissued a “buy” rating on shares of CRISPR Therapeutics in a research note on Friday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of CRISPR Therapeutics in a report on Friday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, CRISPR Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $67.94.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing gene-editing medicines based on CRISPR/Cas9 technology. The company aims to treat serious diseases by precisely modifying genetic material in patients’ cells, with research programs spanning hematology, oncology, autoimmune diseases, and regenerative medicine.

Its lead product, CASGEVY (exagamglogene autotemcel), is a CRISPR/Cas9-based cell therapy developed with Vertex Pharmaceuticals. CASGEVY is approved in multiple markets, including the United States, United Kingdom, and European Union, for certain patients with sickle cell disease and transfusion-dependent beta thalassemia.